The present disclosure relates to crystalline Form ± of a compound of formula (I) used for preparing a blood-cancer drug and preparation method thereof. The crystalline Form ± in the present disclosure has better stability, and its solubility and hygroscopicity meet the requirements of medical use. Form ± has simple preparation method and low manufacturing cost, and provides great value to future optimization and development of this drug.